Payer Perceptions of Fairness in Pricing Rare Disease Therapies
July 31, 2020
The debate over pricing of therapies often centers on the question of value and how to best determine it. The consulting firm Charles River Associates took an interesting approach to understanding the way payers view the pricing of rare therapies. Instead of asking them about pricing in terms of value, they asked about it in terms of fairness. We spoke to Andrew Parece and Matthew Majewski, both vice presidents with Charles River Associates, about how payers view the pricing of rare disease therapies, how context changes perceptions around pricing, and why they began questioning payers about the issue of fairness.
Sign up for updates straight to your inbox.